Journal article

Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Martin Hoenigl, Jon Salmanton-Garcia, Thomas J Walsh, Marcio Nucci, Chin Fen Neoh, Jeffrey D Jenks, Michaela Lackner, Rosanne Sprute, Abdullah MS Al-Hatmi, Matteo Bassetti, Fabianne Carlesse, Tomas Freiberger, Philipp Koehler, Thomas Lehrnbecher, Anil Kumar, Juergen Prattes, Malcolm Richardson, Sanjay Revankar, Monica A Slavin, Jannik Stemler Show all

LANCET INFECTIOUS DISEASES | ELSEVIER SCI LTD | Published : 2021

Abstract

With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes..

View full abstract

Grants

Funding Acknowledgements

MH reports research funding from Gilead, Astellas, Scynexis, and Pfizer; and is supported by the National Institutes of Health. TJW reports grants and personal fees from Allegran, Amplyx, Astellas, Lediant, Medicines Company, Merck, and Scynexis; grant funding from Tetraphase and Viosera, and personal fees from ContraFect, Gilead, Methylgene, and Pfizer. MN reports personal fees from AbbVie, Astellas, Basilea, Bioscana, Gilead, Janssen, Merck Sharp and Dohme, and Pfizer. JDJ reports research grants from Pfizer and support from the National Institutes of Health. MB reports grants and personal fees from Angelini, Astellas, Bayer, Basilea, Cidara, Gilead, Menarini, Merck Sharp and Dohme, Pfizer, Roche, and Shionogi. FC reports personal fees from Astellas, Pfizer, Teva, and United Medical. TF reports personal fees from the Czech Republic Ministry of Health. PK reports non-financial scientific grants from Miltenyi Biotec and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases; and lecture honoraria from, or being an advisor to, Akademie fur Infektionsmedizin, Ambu GmbH, Astellas, European Confederation of Medical Mycology, Gilead Sciences, Gesundheits-und Pflegezentrum Ruesselsheim Academy Ruesselsheim, Merck Sharp and Dohme, Noxxon, and University Hospital of Munich. TL reports grant and personal fees from Gilead; and personal fees from Astellas, Basilea, and Merck Sharp and Dohme. JP reports personal fees from Gilead and Pfizer; and is a stock holder of Gilead. SR reports grants and personal fees from Merck Sharp and Dohme and Pfizer, and support for pharmaceutical company-initiated clinical study paid to institution from Astellas. MAS reports grants from Merck Sharp and Dohme, Gilead, and F2G; and personal fees from Gilead, Merck Sharp and Dohme, and Pfizer. AW reports grant and personal fees from Gilead. J-AHY reports support for pharmaceutical company-initiated clinical studies paid to insitution from Cidara and Scynexis. PH reports support by the Grant of the Czech Ministry of Health (no. NV 17-31269A). RFD reports personal fees from Astellas, Gilead, Merck Sharp and Dohme, and Pfizer. TFP reports grants from Cidara; and personal fees from Basilea, Gilead, Mayne, Merck Sharp and Dohme, Pfizer, Scynexis, Sfunga, and Toyama. TRR reports grants from Menarini and Gilead; and personal fees from Gilead, Menarini, and Pfizer. FQT reports grants from Merck Sharp and Dohme and Pfizer; and personal fees from Teva. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy (CECAD, EXC 2030, 390661388) and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck Sharp and Dohme, Octapharma, Pfizer, and Scynexis; is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck Sharp and Dohme, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi; and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck Sharp and Dohme, and Pfizer. All other authors declare no competing interests.